Sol-Gel to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference
June 16 2020 - 4:05PM
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the
“Company”), a clinical-stage dermatology company focused on
identifying, developing and commercializing branded and generic
topical drug products for the treatment of skin diseases, today
announced the company will present at the BMO 2020 Prescriptions
for Success Healthcare Conference.
Details are as follows: |
|
Speaker: |
Mr. Alon
Seri-Levy, Chief Executive Officer |
Date: |
June 23, 2020 |
Time: |
11:00 am Eastern Time |
A live audio webcast will be available in the Investors/Events
& Presentations section of the Sol-Gel Technologies website at
http://ir.sol-gel.com/events-and-presentations. The webcast replay
will also be available at the same link shortly after the
conclusion of the event for 30 days.
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on
identifying, developing and commercializing branded and generic
topical drug products for the treatment of skin
diseases. Sol-Gel leverages its proprietary
microencapsulation technology platform for Twyneo, for the
treatment of acne vulgaris, and Epsolay, for the treatment of
papulopustular rosacea. The Company’s pipeline also includes
SGT-210, an early-stage topical epidermal growth factor receptor
inhibitor, erlotinib, for the treatment of
punctate palmoplantar keratoderma, and preclinical assets
tapinarof and roflumilast. For additional information, please
visit www.sol-gel.com.
For further information, please contact:Sol-Gel
Contact:Gilad MamlokChief Financial Officer+972-8-9313433
Investor Contact:Lee SternSolebury Trout +1 646 378
2922lstern@soleburytrout.com
Source: Sol-Gel Technologies Ltd.
Sol Gel Technologies (NASDAQ:SLGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sol Gel Technologies (NASDAQ:SLGL)
Historical Stock Chart
From Apr 2023 to Apr 2024